Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
NCT ID: NCT02434692
Last Updated: 2024-12-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2014-07-09
2017-04-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Enrollment will be temporarily halted in case a serious adverse device effect (SADE) occurs, and Data and Safety Monitoring Board (DSMB) meeting will be conducted as soon as possible. The DSMB will then recommend whether to further continue the study as planned, or whether enrollment shall be stopped. In order to provide a complete overview of the study to the DSMB, an interim analysis will be performed after half of the study population (11-14 subjects) is enrolled with a minimum follow-up of 1 month. A conclusion for safety will be made if in total no more than 2 of the total of 22 patients experience a SADE.
The primary aim of this study is to show "safety", which will be evaluated based on the percentage of subjects who experience a SADE (="non-safety"), as defined in the primary endpoints.
The study will be declared a success if the final non-safety event rate is less than 6% (type II error rate of 0.20). The calculation is based on a design optimizing the minimum expected sample size with parameters alpha=0.05, beta=0.20, p0=0.75, p1=0.94.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-arm intervention ARGOS-IO system
The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
ARGOS-IO system
Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARGOS-IO system
Implantation of ARGOS-IO pressure sensor after IOL placement within the cataract surgical procedure on day 0 (V01)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female aged ≥40 and ≤85 years. Female subjects of childbearing potential must be willing to use adequate contraception and must have a negative pregnancy test.
3. Diagnosis of primary open-angle glaucoma (POAG) including high pressure glaucoma (HPG), normal pressure glaucoma (NPG) and ocular hypertension (OH), as defined by the European Glaucoma Society guideline (Heijl, Treverso, et al., 2008)
4. Sufficiently controlled intraocular pressure (IOP)
5. Study eye needs to be phakic
6. Only one eye per patient may be implanted with the ARGOS-IO implant
7. Cataract surgery indicated. The medical indication for a cataract operation must be given irrespective of the study participation. Potential study patients will be solicited for participation in the clinical trial only after the patient has given consent to the cataract operation.
8. Pre-operative anterior chamber depth (ACD) ≥2.0 mm as measured from the corneal endothelium
9. Axis length \>22 mm
10. Endothelial cell density of the cornea ≥2000 cells/mm²
11. Subjects able and willing to attend all scheduled visits and comply with all study procedures
Exclusion Criteria
2. Severe POAG patients with a macular degeneration and visual field loss of -20 decibels (dB) or worse in both eyes. In case of a diverse developed visual field loss, the sensor can be implanted in the worse eye for protection the better eye.
3. Exudative age-related macular degeneration, instable macular degeneration 30 days prior to inclusion, or macular edema
4. Retinal detachment
5. Corneal diseases, especially diseases affecting the corneal endothelium, e.g. Fuchs' Dystrophia
6. Diabetes mellitus
7. Existence of Marfan-Syndrome, Ehlers-Danlos-Syndrome or Weill-Marchesani-Syndrome
8. History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to ARGOS-IO implantation
9. Intraocular surgical procedure(s) within 6 months prior to ARGOS-IO implantation or any surgical procedure such as refractive eye surgery in the study eye that can affect the assessment of IOP by Goldmann applanation tonometry
10. History of eye tumor
11. Ocular disease other than glaucoma that may affect assessment of visual acuity and/or IOP by Goldmann applanation tonometry (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy)
12. Anterior chamber configuration that puts the subject at high risk to develop an angle closure glaucoma
13. History of extensive keloid formation
14. Severe dry eye syndrome
15. Subjects who will need to undergo ancillary procedures in the study eye at the time of implantation or during the post-operative study period
16. Any known intolerance or hypersensitivity to topical anesthetics, mydriatics, plaster or silicone (component of the device)
17. Existence of other active medical eye implant and/or other active medical implants in the head/neck region
18. Any contraindication for intraocular lens (IOL) implantation such as choroidal hemorrhage, concomitant severe eye disease, excessive vitreous loss, extremely shallow anterior chamber, microphthalmos, non-age-related cataract, posterior capsular rupture, severe corneal dystrophy, untraceable IOP, zonular separation, color vision deficiencies
19. Severe generalized disease resulting in a life expectancy shorter than a year
20. Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device
21. Currently pregnant or breastfeeding
22. Participation in any study involving an investigational drug or device within the past 30 days or ongoing participation in a study with an investigational drug or device
23. Patients who are not suitable for the study based on the surgeon's evaluation
24. Patients unable or unwilling to understand or comply with required study procedures
25. Patients with psychiatric disorders influencing their judgement or autonomy
26. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.
27. Enrollment of the fellow eye in this clinical study
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Implandata Ophthalmic Products GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hagen Thieme, Prof.
Role: PRINCIPAL_INVESTIGATOR
University Eye Clinic Magdeburg, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Augenklinik Universitätsklinikum Aachen
Aachen, , Germany
Augen-Zentrum-Nordwest
Ahaus, , Germany
Universitäts-Augenklinik Bochum
Bochum, , Germany
Internationale Innovative Ophthalmochirurgie Breyer-Kaymak-Klabe
Düsseldorf, , Germany
Augenklinik der SLK-Kliniken
Heilbronn, , Germany
nordBLICK Augenklinik Bellevue
Kiel, , Germany
Universitätsaugenklinik Magdeburg
Magdeburg, , Germany
Augenärztliches Augenchirurgisches Zentrum (AAZ)
Nuremberg, , Germany
Klinik und Poliklinik für Augenheilkunde der Universität Rostock
Rostock, , Germany
Knappschaftsklinikum Saar - Augenklinik
Sulzbach, , Germany
Universitäts-Augenklinik
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mansouri K, Gillmann K, Rao HL, Weinreb RN; ARGOS-2 Study Group. Weekly and seasonal changes of intraocular pressure measured with an implanted intraocular telemetry sensor. Br J Ophthalmol. 2021 Mar;105(3):387-391. doi: 10.1136/bjophthalmol-2020-315970. Epub 2020 Jun 4.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Telemetric Measurement of Intraocular Pressure via an Implantable Pressure Sensor-12-Month Results from the ARGOS-02 Trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIV-13-11-011719
Identifier Type: OTHER
Identifier Source: secondary_id
ARGOS-02
Identifier Type: -
Identifier Source: org_study_id